Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

Y0001112

Gestodene

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

(17α)-13-Ethyl-17-hydroxy-18,19-Dinorpregna-4,15-dien-20-yn-3-one, Gestinol, SHB 331, WL 70

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C21H26O2
CAS Number:
60282-87-3
Molecular Weight:
310.43
MDL number:
MFCD00867858
UNSPSC Code:
41116107
PubChem Substance ID:
329831269
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

gestodene

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1C=C[C@@]2(O)C#C

InChI

1S/C21H26O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,10,12-13,16-19,23H,3,5-9,11H2,1H3/t16-,17+,18+,19-,20-,21-/m0/s1

InChI key

SIGSPDASOTUPFS-XUDSTZEESA-N

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Gestodene EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Gestodene is a synthetic progestin used as a contraceptive. Gestodene displays a high binding affinity to the progesterone receptor, and also binds strongly to adrogen and glucocorticoid receptors.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Pictograms

Health hazard
GHS08

Signal Word

Warning

Hazard Statements

H361fd

Precautionary Statements

P201 - P308 + P313

Hazard Classifications

Repr. 2

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Pasquale Florio et al.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 27(6), 434-438 (2011-01-06)
In a retrospective case-control study, we compared the effectiveness of hysteroscopic correction and hormonal treatment to improve symptoms [postmestrual abnormal uterine bleeding (PAUB), pelvic pain localized in suprapubic site] associated with isthmocele. Women (n = 39; mean age ± SD
Ana Cristina Rebelo et al.
The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception, 16(4), 289-297 (2011-07-22)
To evaluate the influence of oral contraceptives (OCs) containing 20 μg ethinylestradiol (EE) and 150 μg gestodene (GEST) on the autonomic modulation of heart rate (HR) in women. One-hundred and fifty-five women aged 24 ± 2 years were divided into
Xiao-Fen Liu et al.
Yao xue xue bao = Acta pharmaceutica Sinica, 45(1), 87-92 (2011-03-01)
To establish a sensitive and specific method for simultaneous determination of gestodene, etonogestrel and ethinylestradiol in plasma by LC-MS/MS, plasma samples were extracted and derivatized before injection. An ESI ion source was used and operated in the positive ion mode
Sille Vaiksaar et al.
Perceptual and motor skills, 113(3), 764-772 (2012-03-13)
Eight female rowers (M age = 21.0 yr., SD = 2.8), using a monophasic oral-contraceptive pill, performed a 1-hr. rowing ergometer test (intensity: 70% VO2max) during the active-pill and non active-pill phases of the oral contraceptive cycle. No significant differences
Lothar A J Heinemann et al.
Contraception, 81(5), 401-407 (2010-04-20)
This study investigated whether gestodene-containing oral contraceptives (OCs) carry a higher risk of venous thromboembolism (VTE) than OCs containing progestins other than desogestrel and gestodene. The study was conducted based on the hypothesis that the biases and confounding factors that
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service